PCL and chitosan NPs |
|
Vaxjo ID |
332 |
|
Vaccine Adjuvant Name |
PCL and chitosan NPs |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
PCL/chitosan NPs were designed with the aim of being able to combine the properties of the 2 polymers in the preparation of an adjuvant for the hepatitis B surface antigen (HBsAg) |
|
Structure |
Polymeric nanoparticles (NPs) made from poly-蔚-caprolactone (PCL) and chitosan. |
|
Preparation |
The nanoparticles were prepared by combining poly-蔚-caprolactone (PCL) and chitosan. |
|
Dosage |
Used at different concentrations, and IgG titers were nanoparticle-dose dependent, but specific dosages are not provided in the abstract. |
|
Function |
Poly-ε-caprolactone (PCL)/chitosan nanoparticles were designed to combine the properties of both polymers as an adjuvant for the hepatitis B surface antigen (HBsAg). |
|
Safety |
The nanoparticles were able to induce higher specific antibody titers without increasing IgE when compared to a commercial vaccine, suggesting a favorable safety profile regarding allergic reactions. |
| References |
Jesus et al., 2018: Jesus S, Soares E, Borchard G, Borges O. Adjuvant Activity of Poly-ε-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-γ and IL-17 Production. Molecular pharmaceutics. 2018; 15(1); 72-82. [PubMed: 29160080].
|
